The average one-year price target for Theraclion (ENXTPA:ALTHE) has been revised to €1.73 per share, as of October 30, 2026.

At least 1,000 women with uterine fibroids and adenomyosis have undergone non-surgical treatment at the Fibroid Care Centre, Nordica, in a major milestone for advanced gynaecological care in Nigeria.

"How is Ulthera Prime different from the conventional Ulthera?" "I heard it's performed while looking at the inside of the ...

Until fairly recently, what these women wanted from a consultation was relatively clear: to erase visible signs of aging, ...

A new review maps how therapeutic ultrasound drives skin repair and regeneration through thermal and mechanical effects, ...

THERACLION (ISIN: FR0010120402; Mnemo: ALTHE), an innovative company developing Sonovein®, a robotic platform for non-invasive varicose vein therapy using High-Intensity Focused Ultrasound (HIFU), ...

Myomectomy for recurrent uterine fibroids after ultrasound treatment, including symptom relief, surgical outcomes, recurrence ...

Learn how to manage pancreatic cancer pain with medications, procedures, and complementary therapies to improve comfort and ...

The upside potential of 189% retained by the research firm, calculated on the closing price of October 26, 2026, is based on ...

If you’ve been to a Hershey Bears game, chances are you’ve heard the voice of Jim “Jonesy” Jones. He’s known for bringing energy and excitement to the crowd, but ...

Auditory hallucinations—or hearing voices that others do not hear—affect more than 70% of people with schizophrenia. Despite ...